Pharmasyntez, the Russian company, has been given a “compulsory license” to make the drug for one year without the permission of Gilead. “The government said in a decree at the time that the move was in the interests of Russia’s own security,” according to the article. “According to the decree, Russia had to pay compensation to the drug’s patent-holder. The amount was not specified.”